|
|
Home
Search
Study Topics
Glossary
|
 |
|
|
|
|
|
|
|
|
|
|
|
|
||||||||||||||||||||||||||||||||||||
| Sponsored by: |
National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK) |
|---|---|
| Information provided by: | National Institutes of Health Clinical Center (CC) |
| ClinicalTrials.gov Identifier: | NCT00001277 |
Purpose
Patients whose parathyroid activity is elevated above normal are referred to as having hyperparathyroidism. This study will help researchers better understand the causes of hyperthyroidism and to evaluate and improve methods for diagnosis and treatment.
In this study, patients diagnosed with or suspected of having hyperparathyroidism will be selected to participate. In addition, patients with related conditions such as parathyroid tumors, will also be selected.
Subjects will be asked to provide blood and urine for testing to confirm their condition. They will then be surgically treated by removal of the parathyroid gland(s) (parathyroidectomy).
Subjects with parathyroid tumors will undergo several diagnostic tests to determine the exact location of the tumor as well as the tumor's activity. The tests may include; ultrasounds, nuclear scanning, CT scans, MRI, and specialized blood testing.
Sometimes parathyroidectomy leads to hypoparathyroidism. Options for treating the patients after the surgical procedure will also be addressed. Calcium and Vitamin D supplements are typically the mainstay of post parathyroidectomy therapy. Other potential treatments include transplanting the parathyroid gland(s) to other areas of the body.
| Condition |
|---|
|
Hyperparathyroidism Hypocalcemia Hypoparathyroidism Parathyroid Neoplasm |
| Study Type: | Observational |
| Official Title: | Studies of Hyperparathyroidism and Related Disorders |
| Study Start Date: | March 1991 |
Patients with confirmed or suspected primary hyperparathyroidism or complications therefrom (such as postoperative hypoparathyroidism) will be admitted for diagnosis and treatment. Patients with moderately severe primary hyperparathyroidism will be treated. The principal diagnostic components are calcium in serum and urine and parathyroid hormone in serum. Patients with moderately severe primary hyperparathyroidism will be treated. Treatment will be mainly by parathyroidectomy.
Preoperative testing to localize parathyroid neoplasm(s) will be used usually and with more extended methods in cases with prior neck surgery.
Preoperative tumor localization tests will be selected according to clinical indications from the following: ultrasound, technetium-thallium scan, computerized tomography, magnetic resonance imaging, fine needle aspiration for parathyroid hormone assay, arteriogram, selective venous catheterization for parathyroid hormone assay. Options for management of postoperative hypocalcemia include calcium, vitamin D analogs, parathyroid autografts and synthetic parathyroid hormone. Research specimens may consist of blood or tumors.
Eligibility| Genders Eligible for Study: | Both |
| Accepts Healthy Volunteers: | No |
Patients (male or female any age) with known or suspected primary hyperparathyroidism or a related disorder (such as familial multiple endocrine neoplasia type 1 [FMEN1]) will be evaluated.
The vast majority of patients will be greater than age 18.
In the rare occasion where special resources might be appropriate (uremic patient, young child), the availability of special resources would be confirmed prior to admission.
EXCLUSION CRITERIA:
There are no absolute exclusions.
Contacts and Locations| Contact: Patient Recruitment and Public Liaison Office | (800) 411-1222 | prpl@mail.cc.nih.gov |
| Contact: TTY | 1-866-411-1010 |
| United States, Maryland | |
| United Services University of Health Services | Recruiting |
| Bethesda, Maryland, United States, 20889 | |
| National Institutes of Health Clinical Center, 9000 Rockville Pike | Recruiting |
| Bethesda, Maryland, United States, 20892 | |
More Information
| Study ID Numbers: | 910085, 91-DK-0085 |
| Study First Received: | November 3, 1999 |
| Last Updated: | July 1, 2009 |
| ClinicalTrials.gov Identifier: | NCT00001277 History of Changes |
| Health Authority: | United States: Federal Government |
|
Parathyroid Calcium Vitamin D |
|
Parathyroid Diseases Hypocalcemia Metabolic Diseases Endocrine System Diseases Calcium, Dietary Parathyroid Neoplasms Vitamin D Hyperparathyroidism |
Head and Neck Neoplasms Vitamins Water-Electrolyte Imbalance Hypoparathyroidism Endocrinopathy Metabolic Disorder Endocrine Gland Neoplasms |
|
Parathyroid Diseases Hypocalcemia Metabolic Diseases Endocrine System Diseases Calcium Metabolism Disorders Parathyroid Neoplasms Neoplasms |
Neoplasms by Site Hyperparathyroidism Head and Neck Neoplasms Water-Electrolyte Imbalance Hypoparathyroidism Endocrine Gland Neoplasms |
